The potential benefits of immunotherapy in the perioperative management of gastric cancer are likely mediated by several mechanisms: (1) Neoadjuvant immunotherapy reactivates tissue-resident memory CD8+ T cells, promoting their expansion and diversification (43, 44). Here, CD8A is linked to gastric cancer.